TTPH - Tetraphase Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.67
+0.01 (+0.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.66
Open3.68
Bid3.45 x 2200
Ask4.47 x 4000
Day's Range3.63 - 3.76
52 Week Range2.05 - 8.75
Volume326,221
Avg. Volume1,392,919
Market Cap189.482M
Beta3.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press17 days ago

    Tetraphase: 1Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 42 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Analysts’ Ratings for Sarepta Therapeutics and Peers in April
    Market Realistlast month

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

  • Tetraphase Pharmaceuticals’ Cash Flow and Price Performance
    Market Realistlast month

    Tetraphase Pharmaceuticals’ Cash Flow and Price Performance

    Tetraphase Pharmaceuticals (TTPH) posted $98.0 million in operating expenses in fiscal 2017, compared with $63.7 million in fiscal 2016. This $34.3 million rise resulted from increased expenses related to the company’s eravacycline Phase 3 studies. Other primary factors included higher drug manufacturing and nonclinical costs in support of its New Drug Application (or NDA) and precommercialization activities for eravacycline.

  • Exploring Tetraphase Pharmaceuticals’ Financial Performance
    Market Realistlast month

    Exploring Tetraphase Pharmaceuticals’ Financial Performance

    Tetraphase Pharmaceuticals (TTPH) generated contract and grant revenues of $9.6 million in fiscal 2017 compared with $5.1 million in fiscal 2016. Until now, the primary source of revenues for the company has been US government contracts. 

  • A Look at Tetraphase Pharmaceuticals’ Target Market
    Market Realistlast month

    A Look at Tetraphase Pharmaceuticals’ Target Market

    Tetraphase Pharmaceuticals (TTPH) is developing eravacycline, a fully synthetic flurocycline for use as a first-line empiric monotherapy for treating multidrug-resistant infections. These infections include gram-negative infections such as those found in complicated intra-abdominal infections (or cIAL).

  • How Analysts View Tetraphase Pharmaceuticals in April 2018
    Market Realistlast month

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

  • Top High Growth NasdaqCM Stocks This Month
    Simply Wall St.last month

    Top High Growth NasdaqCM Stocks This Month

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • Is It The Right Time To Buy Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)?
    Simply Wall St.2 months ago

    Is It The Right Time To Buy Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)?

    Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...

  • Associated Press2 months ago

    Tetraphase reports 4Q loss

    The Watertown, Massachusetts-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Benzinga3 months ago

    Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says

    Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal ...

  • Benzinga3 months ago

    Benzinga Pro's Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) stock ...

  • Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock

    Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.

  • Here's Why Tetraphase Pharmaceuticals Crashed 60.4% Today
    Motley Fool3 months ago

    Here's Why Tetraphase Pharmaceuticals Crashed 60.4% Today

    A key clinical trial failure sent investors fleeing for the exits.

  • Market Exclusive3 months ago

    Here’s What’s Moving Tetraphase

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) didn’t have a great start to the week this week. The company just put out data from a phase 3 clinical trial of one of its lead development assets, a drug called intravenous (IV) eravacycline, and the data has failed to hit the mark on a number of endpoints. In response, […] The post Here’s What’s Moving Tetraphase appeared first on Market Exclusive.

  • 3 Small-Cap Biotech Stocks With Major Catalysts in 2018
    Motley Fool4 months ago

    3 Small-Cap Biotech Stocks With Major Catalysts in 2018

    Good news this year could make these small biotech stocks bigger.

  • InvestorPlace5 months ago

    3 Stocks to Watch on Wednesday: Moneygram International Inc (MGI), Trevena Inc (TRVN) and Tetraphase Pharmaceuticals Inc (TTPH)

    Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.

  • CNBC5 months ago

    After-hours buzz: MGI, TTPH & more

    See which stocks are posting big moves after the bell Tuesday.

  • Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : December 28, 2017
    Capital Cube5 months ago

    Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : December 28, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Tetraphase Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Tetraphase Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTPH-US. Comparing the performance and risk of Tetraphase Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)